[go: up one dir, main page]

WO2013040412A3 - Methods for inhibiting bacteria growth - Google Patents

Methods for inhibiting bacteria growth Download PDF

Info

Publication number
WO2013040412A3
WO2013040412A3 PCT/US2012/055513 US2012055513W WO2013040412A3 WO 2013040412 A3 WO2013040412 A3 WO 2013040412A3 US 2012055513 W US2012055513 W US 2012055513W WO 2013040412 A3 WO2013040412 A3 WO 2013040412A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
bacteria growth
inhibiting bacteria
inhibiting
bacteria
Prior art date
Application number
PCT/US2012/055513
Other languages
French (fr)
Other versions
WO2013040412A2 (en
Inventor
Kenneth F. Blount
Brian R. Dixon
Original Assignee
Biorelix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorelix, Inc. filed Critical Biorelix, Inc.
Publication of WO2013040412A2 publication Critical patent/WO2013040412A2/en
Publication of WO2013040412A3 publication Critical patent/WO2013040412A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to compositions and methods of inhibiting the growth of a bacteria comprising contacting or exposing a bacteria to a compound which binds to a riboswitch to induce expression of at least one gene.
PCT/US2012/055513 2011-09-14 2012-09-14 Methods for inhibiting bacteria growth WO2013040412A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534687P 2011-09-14 2011-09-14
US61/534,687 2011-09-14

Publications (2)

Publication Number Publication Date
WO2013040412A2 WO2013040412A2 (en) 2013-03-21
WO2013040412A3 true WO2013040412A3 (en) 2014-05-08

Family

ID=47883989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055513 WO2013040412A2 (en) 2011-09-14 2012-09-14 Methods for inhibiting bacteria growth

Country Status (1)

Country Link
WO (1) WO2013040412A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098193B2 (en) 2017-10-11 2024-09-24 Institute For Cancer Research Netrin G1 as a biomarker for enhancing tumor treatment efficacy
CN110184326B (en) * 2019-05-13 2022-07-01 华侨大学 TPP riboswitch sequence primer and intestinal flora classification method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019208A1 (en) * 2008-08-11 2010-02-18 Biorelix Pharmaceuticals, Inc. Flavin derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019208A1 (en) * 2008-08-11 2010-02-18 Biorelix Pharmaceuticals, Inc. Flavin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VITRESCHAK ET AL.: "Riboswitches: the oldest mechanism for the regulation of gene expression", TRENDS IN GENETICS, vol. 20, 2004, pages 44 - 50, XP004481965, DOI: doi:10.1016/j.tig.2003.11.008 *

Also Published As

Publication number Publication date
WO2013040412A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
UA110338C2 (en) CHEMICAL COMPOUNDS
WO2012142498A3 (en) Mif inhibitors and their uses
MY160734A (en) Besylate salt of a btk inhibitor
MX341456B (en) Amino-quinolines as kinase inhibitors.
HUE037154T2 (en) Substituted benzylindazole derivatives as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases
EP2831069A4 (en) INHIBITORS OF beta-LACTAMASES DERIVED FROM ISOXAZOLE
EP2729806A4 (en) USES OF MARKED HSP90 INHIBITORS
WO2013003298A3 (en) Inhibitors of pde10
IN2014CN04558A (en)
PH12013501922A1 (en) Protein kinase inhibitors
CL2009000503A1 (en) Preparation process of compounds derived from 2-amino-5-cyanobenzoic acid-3-substituted or 1h-pyrazole-5-carboxamide.
EP3087184A4 (en) Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
MX370253B (en) Compositions of jasmonate compounds and methods of use.
MX344324B (en) Endoprosthesis having an active substance coating.
BR122018074319B8 (en) METHOD FOR PREPARING A COMPOUND OF FORMULA 14
CR20140495A (en) 5-AMINO [1,4] THIAZINES AS INHIBITORS OF BACE1
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
BR112014009775A2 (en) composition, method, seed and compound of formula 1
CA2836511C (en) Matriptase inhibitors and uses thereof against orthomyxoviridae infections
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
WO2014093988A3 (en) Methods and compositions for inhibiting cnksr1
MX2014001510A (en) Anthranilamide compounds and their use as pesticides.
MX348148B (en) Method for promoting plant growth.
WO2011029536A3 (en) Use of cyclic keto-enols for combating plant pathogenic bacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832001

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 27-06-2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12832001

Country of ref document: EP

Kind code of ref document: A2